{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:38:50Z","timestamp":1790721530479,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xops.2025.100913","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:16:02Z","timestamp":1755245762000},"page":"100913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial"],"prefix":"10.1016","volume":"6","author":[{"suffix":"MD, PhD","given":"Tong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han-Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-5587","authenticated-orcid":false,"given":"Huixun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100913_bib1","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1111\/bph.15925","article-title":"Suppression of myeloid PFKFB3-driven glycolysis protects mice from choroidal neovascularization","volume":"179","author":"Liu","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xops.2025.100913_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2025.100913_bib3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.xops.2025.100913_bib4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.xops.2025.100913_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100913_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.xops.2025.100913_bib7","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.xops.2025.100913_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2024.102448","article-title":"The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis","volume":"76","author":"Xu","year":"2024","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.xops.2025.100913_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100913_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.exer.2016.02.004","article-title":"IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys","volume":"145","author":"Ren","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2025.100913_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.oret.2024.08.014","article-title":"Efficacy and safety of Efdamrofusp Alfa versus Aflibercept in participants with neovascular age-related macular degeneration: a randomized, double-masked, active-controlled, noninferiority, phase II trial","volume":"9","author":"Sun","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100913_bib12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0140-6736(25)00672-5","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"405","author":"Hopewell","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100913_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","article-title":"Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review","volume":"42","author":"Chaudhary","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100913_bib14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100913_bib15","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xops.2025.100913_bib16","article-title":"Comparative study on the efficacy of conbercept and aflibercept in the treatment of neovascular age-related macular degeneration","volume":"14","author":"Xie","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.100913_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1167\/iovs.07-1132","article-title":"Report from the NEI\/FDA ophthalmic clinical trial design and endpoints symposium","volume":"49","author":"Csaky","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100913_bib18","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/s41433-022-02360-4","article-title":"Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review","volume":"37","author":"Hanson","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.xops.2025.100913_bib19","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xops.2025.100913_bib20","first-page":"2374","article-title":"Visual acuity response profiles in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial","volume":"50","author":"Eldem","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100913_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100913_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","article-title":"A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration","volume":"50","author":"Schmidt-Erfurth","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.100913_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.13.1.29","article-title":"Texture-based radiomic SD-OCT features associated with response to Anti-VEGF therapy in a phase III neovascular AMD clinical trial","volume":"13","author":"Sil","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2025.100913_bib24","first-page":"1160","article-title":"Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis","volume":"37","author":"Schmidt-Erfurth","year":"2023","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.xops.2025.100913_bib25","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1038\/s41598-021-87340-6","article-title":"Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease","volume":"11","author":"Tanaka","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.100913_bib26","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41467-020-14499-3","article-title":"Increased circulating levels of factor H-Related protein 4 are strongly associated with age-related macular degeneration","volume":"11","author":"Cipriani","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.xops.2025.100913_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.61.8.15","article-title":"Geographic atrophy: confocal scanning laser ophthalmoscopy, histology, and inflammation in the region of expanding lesions","volume":"61","author":"Bonilha","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100913_bib28","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41598-018-25557-8","article-title":"Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy","volume":"8","author":"Katschke","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.100913_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis Re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.100913_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nri3459","article-title":"Immunology of age-related macular degeneration","volume":"13","author":"Ambati","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xops.2025.100913_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100913_bib32","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/jof7110996","article-title":"Fungal endophthalmitis: a comprehensive review","volume":"7","author":"Haseeb","year":"2021","journal-title":"J Fungi"}],"updated-by":[{"DOI":"10.1016\/j.xops.2025.101002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:43:54Z","timestamp":1772919834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666914525002118"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100913","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100913"}}